People · Operator
Named in public records as an officer, director or promoter · active 2014–2024 · Biotechnology, Pharma, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| RayzeBio, Inc. | — | Biotechnology | Series D+ | $396.4M | $3.4B | 2020 |
| Avalo Therapeutics, Inc. | — | Biotechnology | Series D+ | $181.8M | $1.6B | 2024 |
| Corvidia Therapeutics, Inc. | — | Biotechnology | Series C | $60.0M | $2.5B | 2018 |
| Akero Therapeutics, Inc. | — | Pharma | Series C | $45.5M | $1.6B | 2018 |
| Syntimmune, Inc. | — | Biotechnology | Series B | $26.0M | $714.4M | 2017 |
| Cure Forward Corp. | — | Other Technology | Series A | $16.3M | $124.8M | 2014 |
Aaron Kantoff at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Aaron Kantoff on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Seth Harrison | 2 | 19 |
| Aaron Royston | 2 | 7 |
| Kevin Bitterman | 1 | 15 |
| Isaac Blech | 1 | 14 |
| Jerel Davis | 1 | 13 |
| EUGENE A. BAUER | 1 | 7 |
| Geeta Vemuri | 1 | 7 |
| Sol J. Barer | 1 | 6 |
| Maha Katabi | 1 | 6 |
| Tyrell Rivers | 1 | 6 |
| Mark Iwicki | 1 | 4 |
| Phil Gutry | 1 | 4 |
| Behshad Sheldon | 1 | 3 |
| Christopher Sullivan | 1 | 3 |
| ULI HACKSELL | 1 | 3 |
| Magnus Persson | 1 | 3 |
| Isaac A. Blech | 1 | 3 |
| Frank Ingari | 1 | 3 |
| Frank A. Torti | 1 | 3 |
| Eugene Bauer | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.